Appearing as a noteworthy advance in the fight against obesity, this medication is attracting considerable buzz. This treatment combines properties of two established GLP-1 receptor agonists, semaglutide , and an additional glucose-dependent incretin component. Early study results have indicated impressive weight decrease in people with a high BMI